MARKHAM, Ontario, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of December 2023, representing $0.936 per Common Share on an annualized basis.
The dividend will be payable on January 15, 2024 to shareholders of record as at December 29, 2023.
The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.
About Sienna Senior Living
Sienna Senior Living Inc. (TSX:SIA) offers a full range of seniors' living options, including independent living and assisted living under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna's approximately 12,000 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.
For further information, please contact: David Hung Chief Financial Officer & Executive Vice President (905) 489-0258 [email protected]
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which...
Agenus Inc. ("Agenus") , a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule...
VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce significant organizational changes to further strengthen its leadership team as it prepares for accelerated growth and enhanced operational efficiency. The Company has promoted...
RS Oncology, a clinical-stage biopharmaceutical company focused on developing novel treatments for aggressive and rare cancers, today announced that it will present the complete Phase 1 dose escalation data as an oral presentation at the world's...
Merck , known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and...
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today...
